報價延遲最少15分鐘:2026/03/10 01:56 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.11 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.21/--
|
|
企業價值
57.13M
|
| 資產負債 |
|
每股賬面淨值
-0.37
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs. |
